Help appealing denials for this first approved treatment for bronchiectasis.

Appeal Your Brinsupri Denial

Get access to the first and only treatment specifically approved for bronchiectasis.

Understanding Your Brinsupri (brensocatib) Denial

Brinsupri (brensocatib) is the first and only medication specifically approved for non-cystic fibrosis bronchiectasis in adults and adolescents 12 years and older. Bronchiectasis causes recurring lung infections and progressive lung damage. If you have this condition, you finally have a targeted treatment option.

Common Reasons for Denial

! Prior authorization required
! Bronchiectasis diagnosis not documented by CT
! Exacerbation history not provided
! Must try antibiotics/airway clearance first
! New drug with limited coverage policies
! High-cost specialty medication

How We Help

We help you document your bronchiectasis diagnosis, CT scan findings, exacerbation history, prior treatments, and the impact on your quality of life to demonstrate medical necessity.

Start your Brinsupri appeal — it takes about 3 minutes.

Some Types of Evidence We Can Use For Supporting Your Appeal

✓ Brensocatib inhibits DPP1, reducing neutrophil serine protease activity and inflammation in bronchiectatic airways.

✓ Clinical trials demonstrated a 21% reduction in annual exacerbation rate with brensocatib treatment.

✓ Non-cystic fibrosis bronchiectasis has had no approved disease-modifying treatments until now.

✓ Reducing exacerbations preserves lung function and improves quality of life in bronchiectasis patients.

Financial Assistance Directory

Curated copay foundations, manufacturer programs, and safety-net clinics that may help with the cost while you appeal.

For your condition

Cystic Fibrosis Foundation Compass (opens in a new tab)

1-on-1 navigation for CF patients on insurance, financial, and legal questions. Free service.

Phone: 1-844-COMPASS

General copay foundations & directories

NeedyMeds (opens in a new tab)

Searchable database of 5,000+ patient assistance, copay, and diagnosis-specific programs. Start here if you are not sure where to look.

Eligibility: No eligibility check - the directory itself is free. Individual programs have their own income and insurance criteria.

Patient Advocate Foundation Co-Pay Relief (opens in a new tab)

Direct copay assistance for insured patients with chronic, life-threatening, or rare conditions. Covers many disease funds.

Eligibility: Generally requires insurance coverage and income up to 400% of the federal poverty level (varies by fund).

Phone: 1-866-512-3861

HealthWell Foundation (opens in a new tab)

Independent charity providing copay, premium, and travel assistance grants across 70+ disease funds.

Eligibility: Must have insurance covering the prescribed treatment; income thresholds vary by fund. Funds open and close as donations allow.

The Assistance Fund (TAF) (opens in a new tab)

Copay, insurance premium, and travel assistance for patients with chronic and rare diseases.

Eligibility: Must have insurance and meet income limits (typically up to 500% FPL, fund-dependent).

Good Days (opens in a new tab)

Copay assistance and other support for chronic-disease patients.

Eligibility: Funds vary by disease and open/close based on availability. Usually requires insurance and income under ~500% FPL.

PAN Foundation (Patient Access Network) (opens in a new tab)

Disease-specific copay assistance funds for ~70 conditions. Funds open and close throughout the year - check the website or sign up for fund-open alerts.

Eligibility: Insurance required; income limits typically 400-500% of FPL depending on the fund.

NORD (National Organization for Rare Disorders) (opens in a new tab)

Patient assistance, copay, and travel programs for people living with rare diseases.

RxAssist Patient Assistance Program Center (opens in a new tab)

Comprehensive directory of manufacturer patient assistance programs. Search by medication to find the manufacturer's free-drug program if you are uninsured or under-insured.

Safety-net clinics & 340B

HRSA Find a Health Center (FQHC locator) (opens in a new tab)

Federally Qualified Health Centers (FQHCs) provide primary care on a sliding-fee scale and dispense many medications at 340B-discounted prices, regardless of insurance status. Often the cheapest path for uninsured or under-insured patients.

HRSA 340B Program (provider directory + program info) (opens in a new tab)

Background on the 340B Drug Pricing Program. Use to verify whether a particular clinic or hospital is a covered entity before assuming discounted pricing applies.

State Pharmaceutical Assistance Program (SPAP) directory (opens in a new tab)

State-run programs (mostly for seniors and people with disabilities) that supplement Medicare Part D and reduce prescription costs. Availability and benefits vary by state.

Medicaid eligibility & application (Healthcare.gov) (opens in a new tab)

If denied insurance is unaffordable, check Medicaid / CHIP eligibility - thresholds and pathways vary by state, and many expansion states cover adults up to 138% FPL.

Program eligibility, fund availability, and contact info change frequently. Verify with each organization before assuming a program is open.

Patient Assistance & Copay Programs

These programs may help reduce your costs while you appeal:

inLighten Patient Support (Insmed)

Copay assistance for commercially insured patients. Patient support program offers insurance navigation and access assistance. Contact Insmed for details.

Eligibility requirements and program terms may change. Please verify current details directly with each organization.

Patient Advocacy & Support Organizations

These organizations provide education, support, and advocacy for patients:

Pulmonary Fibrosis Foundation

Largest nonprofit dedicated to pulmonary fibrosis research and patient support. Help Center: 844.TalkPFF.

Frequently Asked Questions

Include your high-resolution CT scan showing bronchiectasis, history of pulmonary exacerbations (typically 2 or more in the past year), sputum culture results, and documentation of current management with airway clearance and antibiotics.

Brinsupri inhibits dipeptidyl peptidase 1 (DPP1), which reduces neutrophil-mediated inflammation and damage in the airways. This helps reduce exacerbations and slow disease progression.

No, Brinsupri is specifically approved for non-cystic fibrosis bronchiectasis. You must have bronchiectasis from other causes (infections, immune deficiency, etc.) to be eligible.

Ready to Fight Your Brinsupri (brensocatib) Denial?

Our free AI-powered tool will help you generate a compelling appeal letter in minutes.

Start Your Appeal Chat with AI Assistant

Disclaimer: Fight Health Insurance is not affiliated with, endorsed by, or partnered with any pharmaceutical manufacturer, healthcare provider, medical device company, or patient assistance program, including Insmed Incorporated. All information provided is for educational and informational purposes only and does not constitute medical or legal advice. Please consult with your healthcare provider regarding treatment options and with your insurance company regarding coverage decisions.